Treatment of Microscopic Disease with Hyperthermic Intraoperative Intraperitoneal Chemotherapy After Complete Cytoreduction Improves Disease-Free Survival in Patients with Stage IIIC/IV Ovarian Cancer

Abstract

The treatment of the microscopic disease following complete cytoreduction with HIPEC in patients with advanced ovarian cancer is effective and can prolong disease-free survival. This survival benefit was not seen in undifferentiated tumors.

Feasibility of hyperthermic pressurized intraperitoneal aerosol chemotherapy in a porcine model

“…[5]. Combined CRS and HIPEC against peritoneal carcinomatosis of colorectal, gynecological, and gastric origin appear to be superior to other treatment methods [7,8,16]. Solass et al developed PIPAC, which might be superior to HIPEC in theory.…”

Hyperthermic Intraperitoneal Perfusion Chemotherapy and Cytoreductive Surgery for Controlling Malignant Ascites From Ovarian Cancer

“…1 Long-term OS has been reported to be less than 8 months in the most end-stage patients with OC. 25,37,41 The efficacy of HIPEC and CRS for treating PC originating from advanced OC is well established, and the survival obtained using HIPEC + CSR seems to be dramatically longer than that obtained with previously reported treatment approaches. 25,37,41 The present study indicates that HIPEC + CSR can be tailored according to the patient's general condition.…”

“…25,37,41 The efficacy of HIPEC and CRS for treating PC originating from advanced OC is well established, and the survival obtained using HIPEC + CSR seems to be dramatically longer than that obtained with previously reported treatment approaches. 25,37,41 The present study indicates that HIPEC + CSR can be tailored according to the patient's general condition. Furthermore, patients in poor general health condition who are initially ineligible for CRS can receive the benefits of dCRS several days after the administration of HIPEC, which improves their health condition, thereby potentially increasing long-term survival.…”

“…17,19Y28 Cytoreductive surgery plus HIPEC with cisplatin 29 or carboplatin combined with paclitaxel 30,31 has been reported to show good clinical efficacy in terms of the QOL and survival of patients with OC 32Y34 or recurrent OC, 35Y39 although it remains to be definitively established whether the addition of HIPEC to CRS confers a survival benefit. 35,40,41 However, the general health condition of patients with OC and large-volume ascites varies widely, and some patients with OC and large-volume ascites are not eligible for CRS because of poor general health condition and unstable vital signs. 1,3,5 Consequently, HIPEC using minimally invasive surgical approaches, such as laparoscopic or B-mode ultrasoundguided placement of perfusion catheters, has recently been proposed for patients not eligible for CRS.…”

Neoadjuvant, adjuvant and long-term intravenous/intraperitoneal chemotherapy, hyperthermic intraperitoneal chemotherapy, early postoperative intraperitoneal chemotherapy for ovarian cancer

“…Cascales-Campos et al 56 studied 87 patients, 52 of whom were treated with HIPEC (paclitaxel) and 35 were in the control group. The result showed that the 1 year disease-free survival was 81% vs 66,0% and 3 year disease-free survival was 63.0% vs 18.0% (P<0.05).…”